A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Study Summary

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Conditions

Schizophrenia Schizoaffective Disorder Bipolar Disorder Major Depressive Disorder Tardive Dyskinesia

Interventions / Drugs

Valbenazine

View on ClinicalTrials.gov ↗

Sponsor

NBIX

Neurocrine Biosciences

Neuroscience

D50/100

Study Details

Enrollment50 participants

Primary Completion—

Lead SponsorNeurocrine Biosciences

Data Retrieved2026-04-11 04:22:17.614547+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.